ONCOLYTICS BIOTECH INC 8-K

What Happened
On February 4, 2026, Oncolytics Biotech, Inc. (ONCY) filed a Form 8‑K (Item 8.01) and issued a press release announcing that the U.S. Food and Drug Administration granted Fast Track Designation for pelareorep administered in combination with bevacizumab, leucovorin, fluorouracil and irinotecan (FOLFIRI) for use in second‑line treatment of KRAS‑mutant, microsatellite‑stable metastatic colorectal cancer. The press release is attached to the filing as Exhibit 99.1.

Key Details

• Date filed: February 4, 2026 (Form 8‑K, Item 8.01).
• Regulatory action: FDA Fast Track Designation awarded.
• Treatment regimen: pelareorep + bevacizumab + leucovorin + fluorouracil + irinotecan (FOLFIRI).
• Indication: second‑line KRAS‑mutant, microsatellite‑stable (MSS) metastatic colorectal cancer.
• Filing includes press release as Exhibit 99.1; 8‑K signed by CFO Kirk Look.

Why It Matters
Fast Track status is a regulatory milestone that can help speed development and review of a therapy by facilitating more frequent FDA interactions and potentially enabling rolling review and priority review pathways. For investors, this designation is a formal recognition from the FDA that the pelareorep + FOLFIRI program addresses an unmet need in a defined patient population, which may increase the program’s regulatory focus and could affect the company’s development timeline. The 8‑K does not disclose new clinical data or changes to trial design.